Sionna Therapeutics’ (SION) “Buy” Rating Reaffirmed at BTIG Research

BTIG Research restated their buy rating on shares of Sionna Therapeutics (NASDAQ:SION) in a research report sent to investors on Monday,Benzinga reports. BTIG Research currently has a $58.00 target price on the stock.

A number of other equities research analysts also recently weighed in on SION. Citizens Jmp started coverage on Sionna Therapeutics in a report on Tuesday, February 24th. They set a “market outperform” rating and a $63.00 price objective on the stock. Citigroup initiated coverage on Sionna Therapeutics in a report on Tuesday, February 24th. They issued an “outperform” rating for the company. UBS Group restated a “buy” rating on shares of Sionna Therapeutics in a research report on Monday, March 2nd. Lifesci Capital raised Sionna Therapeutics to a “strong-buy” rating in a research note on Wednesday, February 25th. Finally, Raymond James Financial reiterated a “strong-buy” rating and set a $53.00 price objective on shares of Sionna Therapeutics in a research note on Monday, January 5th. Two investment analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $50.57.

Sionna Therapeutics Price Performance

Shares of Sionna Therapeutics stock opened at $39.21 on Monday. Sionna Therapeutics has a 52-week low of $10.97 and a 52-week high of $46.46. The firm has a market capitalization of $1.76 billion, a PE ratio of -20.11 and a beta of 3.01. The company’s fifty day moving average price is $38.13 and its two-hundred day moving average price is $38.94.

Sionna Therapeutics (NASDAQ:SION) last released its quarterly earnings data on Monday, March 2nd. The company reported ($0.46) EPS for the quarter, topping analysts’ consensus estimates of ($0.61) by $0.15. Analysts predict that Sionna Therapeutics will post -2.44 earnings per share for the current fiscal year.

Insider Activity at Sionna Therapeutics

In other news, Director Orbimed Advisors Llc sold 2,948 shares of the firm’s stock in a transaction that occurred on Saturday, April 18th. The shares were sold at an average price of $44.52, for a total transaction of $131,244.96. Following the completion of the sale, the director owned 2,964,774 shares of the company’s stock, valued at approximately $131,991,738.48. This trade represents a 0.10% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Peter A. Thompson sold 2,948 shares of the business’s stock in a transaction that occurred on Saturday, April 18th. The stock was sold at an average price of $44.52, for a total value of $131,244.96. Following the completion of the transaction, the director directly owned 2,964,774 shares in the company, valued at $131,991,738.48. The trade was a 0.10% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 1,193,762 shares of company stock valued at $53,594,505. Company insiders own 3.90% of the company’s stock.

Institutional Trading of Sionna Therapeutics

Large investors have recently made changes to their positions in the business. TD Asset Management Inc raised its holdings in shares of Sionna Therapeutics by 74.3% in the third quarter. TD Asset Management Inc now owns 87,082 shares of the company’s stock valued at $2,561,000 after buying an additional 37,116 shares during the last quarter. China Universal Asset Management Co. Ltd. bought a new stake in Sionna Therapeutics during the 3rd quarter worth about $147,000. Artia Global Partners LP acquired a new stake in Sionna Therapeutics in the 4th quarter valued at about $4,926,000. Eventide Asset Management LLC acquired a new stake in Sionna Therapeutics in the 4th quarter valued at about $26,290,000. Finally, ProShare Advisors LLC bought a new position in shares of Sionna Therapeutics in the fourth quarter worth about $202,000.

About Sionna Therapeutics

Sionna Therapeutics is a clinical-stage biotechnology company dedicated to developing next-generation RNA therapeutics for oncology and immunology indications. Leveraging proprietary lipid nanoparticle and coacervate delivery technologies, the company aims to overcome key challenges associated with stability, targeting and immune activation that have historically limited the clinical performance of mRNA-based medicines. Its strategic focus spans both solid tumors and hematological malignancies, as well as selected autoimmune disorders, reflecting a broad ambition to harness the power of messenger RNA in diverse therapeutic areas.

At the heart of Sionna’s approach is a platform that combines optimized ionizable lipids with bespoke surface chemistries to enhance payload delivery, intracellular release and endosomal escape.